Dannel Yeo1, Xiaoqi Liang2, Althea Bastian3

  • 1Li Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, New South Wales, Australia; Precision Oncology Laboratory, Cancer Innovations, Centenary Institute, Camperdown, New South Wales, Australia; Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, New South Wales, Australia.

まとめ

頭頸部粘膜扁平上皮癌(HNmSCC)患者における循環腫瘍細胞(CTC)の検出は、独立した予後価値を示す。CTC高値は再発を予測し、個別化治療のためのリスク層別化に役立つ。